Lifesci Capital Predicts Immunome FY2024 Earnings
Equities research analysts at Lifesci Capital issued their FY2024 earnings per share (EPS) estimates for shares of Immunome in a note issued to investors on Tuesday, March 11th. Lifesci Capital ...
LifeSci Capital Initiates a Buy Rating on Zymeworks (ZYME)
LifeSci Capital analyst Charles Zhu initiated coverage with a Buy rating on Zymeworks (ZYME – Research Report) today and set a price target of ...
What is Lifesci Capital’s Forecast for TARA Q1 Earnings?
Investment analysts at Lifesci Capital issued their Q1 2025 EPS estimates for Protara Therapeutics in a note issued to ...
Molecular Partners (MOLN) Initiated with a Buy at LifeSci Capital
In a report released today, Charles Zhu from LifeSci Capital initiated coverage with a Buy rating on Molecular Partners (MOLN – Research ...
Fintel on MSN4 天
LifeSci Capital Initiates Coverage of Immunome (IMNM) with Outperform Recommendation
Fintel reports that on March 11, 2025, LifeSci Capital initiated coverage of Immunome (NasdaqCM:IMNM) with a Outperform ...
Fintel on MSN3 天
LifeSci Capital Initiates Coverage of Monte Rosa Therapeutics (GLUE) with Outperform ...
Fintel reports that on March 12, 2025, LifeSci Capital initiated coverage of Monte Rosa Therapeutics (NasdaqGS:GLUE) with a ...
Nasdaq12 天
LifeSci Capital Initiates Coverage of Monte Rosa Therapeutics (GLUE) with Outperform ...
Fintel reports that on March 12, 2025, LifeSci Capital initiated coverage of Monte Rosa Therapeutics (NasdaqGS:GLUE) with a Outperform recommendation. As of March 4, 2025, the average one-year ...
Nasdaq12 天
LifeSci Capital Initiates Coverage of Molecular Partners AG - Depositary Receipt () (MOLN ...
Fintel reports that on March 11, 2025, LifeSci Capital initiated coverage of Molecular Partners AG - Depositary Receipt () (NasdaqGS:MOLN) with a Outperform recommendation. As of March 4 ...